Study of ovarian cancer management

Ovarian cancer is the most lethal gynecological malignancy. Many patients present at an advanced stage as the symptoms of early stage disease can be vague. AIM We evaluated the demographics, treatment regimens and survival rates of ovarian cancer patients attending Beaumont Hospital Dublin over a ni...

Full description

Saved in:
Bibliographic Details
Published in:Irish medical journal 2006-10, Vol.99 (9), p.279-280
Main Authors: Gaughan, E, Javaid, T, Cooley, S, Byrne, P, Gaughan, G
Format: Article
Language:English
Subjects:
Adult
Cystadenocarcinoma, Papillary - diagnosis
Cystadenocarcinoma, Papillary - mortality
Cystadenocarcinoma, Papillary - pathology
Cystadenocarcinoma, Papillary - surgery
Cystadenocarcinoma, Serous - diagnosis
Cystadenocarcinoma, Serous - mortality
Cystadenocarcinoma, Serous - pathology
Cystadenocarcinoma, Serous - surgery
Female
Humans
Neoplasm Staging
Ovarian Neoplasms - diagnosis
Ovarian Neoplasms - mortality
Ovarian Neoplasms - pathology
Ovarian Neoplasms - surgery
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ovarian cancer is the most lethal gynecological malignancy. Many patients present at an advanced stage as the symptoms of early stage disease can be vague. AIM We evaluated the demographics, treatment regimens and survival rates of ovarian cancer patients attending Beaumont Hospital Dublin over a nine year period. A retrospective chart review of ovarian cancer patients attending Beaumont Hospital between 11/10/94 and 30/6/3 was performed. Patients were selected from pathology records. Patients with borderline histology and those who died of unrelated causes were excluded. 31% of individuals presented with distension as their only clinical sign. 20% presented with a mass as their only clinical sign. The most common cell type was papillary serous adenocarcinoma in two thirds of cases. 54% presented with advanced disease [stage IIl-IV]. Treatment involved surgical clearance or debulking +/- chemotherapy. 5 year survival for Stage I was 95% versus 19% for Stage IlI. This highlights the importance of early diagnosis.
ISSN:0332-3102